Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization.
Curr. Diab. Rep. 8, 87-93 (2008)
Mucosal administration of insulin represents an attractive antigen-specific therapeutic approach to preventing type 1 diabetes. It can prevent autoimmune diabetes in animal models, but although it has been shown to be safe, it has not yet been proven effective in human studies. Efficacy may depend on the dose and route at which insulin is administered, the stage in type 1 diabetes pathogenesis at which treatment is initiated, and the study cohort that is treated. We have proposed Pre-POINT (Primary Oral/intranasal INsulin Trial), a dose-finding safety and immune efficacy pilot study for primary mucosal insulin therapy in islet autoantibody-negative children at high genetic risk for type 1 diabetes who naturally first develop autoimmunity to insulin. Pre-POINT aims to identify an optimal insulin dose and route of application (orally or intranasally) that is well tolerated and can induce an immune response to insulin for additional use in a phase II/III primary prevention trial in children at risk.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
0.000
0.590
63
66
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Language
english
Publication Year
2008
HGF-reported in Year
0
ISSN (print) / ISBN
1534-4827
e-ISSN
1539-0829
Journal
Current Diabetes Reports
Quellenangaben
Volume: 8,
Issue: 2,
Pages: 87-93
Publisher
Springer
Publishing Place
Heidelberg [u.a.]
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes Research (IDF)
Institute of Diabetes and Obesity (IDO)
Institute of Pancreatic Islet Research (IPI)
Institute of Diabetes and Obesity (IDO)
Institute of Pancreatic Islet Research (IPI)
POF-Topic(s)
30201 - Metabolic Health
30502 - Diabetes: Pathophysiology, Prevention and Therapy
30502 - Diabetes: Pathophysiology, Prevention and Therapy
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502100-001
G-502290-001
G-502290-001
PubMed ID
18445349
WOS ID
000261100300002
Erfassungsdatum
2008-04-30